SEC-sourced researchBeta
MCRB
Seres Therapeutics, Inc.
Company comparison ↗
Data passport
- CIK
- 0001609809
- Exchange
- Nasdaq
- Business activity
- — · SIC 2834
- Financial inputs
- 6/6
- Filing date
- Mar 12, 2026
- SEC registry record
- Operating company
Annual financial history
Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.
| Period end | Revenue | Filing date |
|---|---|---|
| December 2023 | 0.0000 | Mar 12, 2026 |
| December 2024 | 0.0000 | Mar 12, 2026 |
| December 2025 | 789,000.0000 | Mar 12, 2026 |
Annual periods · USD
| Period end | Revenue | Net income | Operating cash flow | Total assets | Total liabilities | Filing date |
|---|---|---|---|---|---|---|
| December 2025 | 789,000.0000 | 5,696,000.0000 | 1,117,000.0000 | 138,193,000.0000 | 93,975,000.0000 | Mar 12, 2026 |
| December 2024 | 0.0000 | 136,000.0000 | -148,609,000.0000 | 139,810,000.0000 | 126,026,000.0000 | Mar 12, 2026 |
| December 2023 | 0.0000 | -113,724,000.0000 | -117,354,000.0000 | — | — | Mar 12, 2026 |
Financial inputs behind the calculation
| Financial inputs | USD | Period end | Filing date | Form |
|---|---|---|---|---|
| RevenueRevenues | $789K | December 2025 | Mar 12, 2026 | 10-K |
| Previous period revenueRevenues | $0 | December 2024 | Mar 12, 2026 | 10-K |
| Net incomeNetIncomeLoss | $5.7M | December 2025 | Mar 12, 2026 | 10-K |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | $1.12M | December 2025 | Mar 12, 2026 | 10-K |
| Total assetsAssets | $138.19M | December 2025 | Mar 12, 2026 | 10-K |
| Total liabilitiesLiabilities | $93.98M | December 2025 | Mar 12, 2026 | 10-K |